Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: a double-blind, randomised, phase 1 trial

BACKGROUND: To mitigate the effects of COVID-19, a vaccine is urgently needed. BBV152 is a whole-virion inactivated SARS-CoV-2 vaccine formulated with a toll-like receptor 7/8 agonist molecule adsorbed to alum (Algel-IMDG) or alum (Algel). METHODS: We did a double-blind, multicentre, randomised, con...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Lancet Infect Dis
Autori principali: Ella, Raches, Vadrevu, Krishna Mohan, Jogdand, Harsh, Prasad, Sai, Reddy, Siddharth, Sarangi, Vamshi, Ganneru, Brunda, Sapkal, Gajanan, Yadav, Pragya, Abraham, Priya, Panda, Samiran, Gupta, Nivedita, Reddy, Prabhakar, Verma, Savita, Kumar Rai, Sanjay, Singh, Chandramani, Redkar, Sagar Vivek, Gillurkar, Chandra Sekhar, Kushwaha, Jitendra Singh, Mohapatra, Satyajit, Rao, Venkat, Guleria, Randeep, Ella, Krishna, Bhargava, Balram
Natura: Artigo
Lingua:Inglês
Pubblicazione: Elsevier Ltd. 2021
Soggetti:
Articles
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC7825810/
https://ncbi.nlm.nih.gov/pubmed/33485468
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S1473-3099(20)30942-7
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi